Sensorion SA

Sensorion’s SENS‑501 trial clears safety hurdles, boosting confidence in its vestibular‑ear therapy and driving a 217% stock swing as biotech hopes rise.

Sensorion SA, a biopharmaceutical company focused on treating inner ear diseases, faces financial challenges and uncertainty, but remains committed to innovation and development.